CSG's Owner Bets €987 Million on Pirelli While the Defence Group Chases Munitions Independence
Published on 08/05/2026 at 17:04 | Redaktion boerse-global.de
The Czechoslovak Group has spent the past month delivering a steady stream of headlines, but the two most consequential moves — one personal, one corporate — point in strikingly different directions. While the defence conglomerate's billionaire owner has been diversifying his private wealth into Italian tyres, the company itself is doubling down on the business of making war materiel, from artillery propellant to hypersonic interceptors.
A Reifen Giant Enters the Portfolio
Michal Strnad, CSG's chief executive, has taken a 14 percent stake in Pirelli through his private vehicle Lumina Crown, paying €6.50 per share in a transaction worth roughly €987 million. The seller was Chinese state-owned Sinochem, and the deal vaults Strnad into position as the tyre maker's third-largest shareholder. Analysts read the purchase as a deliberate broadening of his industrial holdings — CSG remains the anchor of his empire, but the bet on Pirelli signals a willingness to look beyond defence for returns.
The timing is notable. European defence contractors are wrestling with what industry observers call the "supply-chain paradox": demand for ammunition has never been higher, yet the raw materials needed to produce it remain stubbornly scarce. Strnad's private move into tyres — a sector with entirely different dynamics — offers a hedge against the volatility of his core business.
Vertical Integration in Saxony
On the corporate side, CSG is attacking that supply-chain problem head-on. The group has acquired a 57-hectare industrial site in Gnaschwitz, near Bautzen in Saxony, from MAXAM, with plans to invest over €100 million in production of nitroglycerin and other propellant precursors. The facility is expected to create up to 125 jobs.
The strategic logic is straightforward: by manufacturing the chemistry itself, CSG insulates its ammunition lines from external suppliers and their bottlenecks. The company aims to lift annual large-calibre ammunition output from 550,000 units last year to 850,000 by the end of 2026 — an ambitious ramp that depends on exactly the kind of self-sufficiency the Gnaschwitz plant is designed to deliver.
A Canadian Bet on the Drone Wars
That push into conventional munitions runs in parallel with a more futuristic play. Through its corporate fund Tech Horizons, CSG took a stake in May in North Vector Dynamics, a Calgary-based developer of missile systems specialising in autonomy, precision interception and hypersonic technologies. The start-up, founded in 2022 and closely linked to the University of Calgary, counts NASA veteran Paul Ziade among its founders. Its focus on low-cost counter-drone interceptors reflects lessons from the war in Ukraine, where cheap drone swarms have proven devastating and expensive to counter.
CSG management has framed the Canadian investment as a strategic response to that conflict's battlefield realities. The group, which describes itself as a global industrial concern with production sites on three continents and more than 14,000 employees, is effectively building a two-track defence portfolio: volume ammunition production for current conflicts, and next-generation interception technology for the ones that may follow.
Handling hazardous substances safely is a legal duty for any employer — and as defence manufacturers scale up production of propellants and precursors, the risks only grow. A free COSHH toolkit with 43 ready-to-use templates and checklists helps you meet your legal obligations for assessing dangerous substances without hours of paperwork. Download the free COSHH Toolkit
A Market Primed for Missile Defence
The broader environment favours both bets. Western governments are pouring money into missile defence at an unprecedented rate. The Pentagon has signed framework agreements with Northrop Grumman and Lockheed Martin to triple production of Patriot interceptors and quadruple THAAD systems, with a long-term goal of acquiring nearly 14,000 interceptors. The Center for Strategic and International Studies estimates US stockpiles are already two-thirds depleted after the conflicts in Iran and Ukraine. That replenishment cycle is driving investment across the sector — precisely the tailwind CSG is trying to catch.
The Share Price Tells Its Own Story
Investors have taken notice. The stock has climbed roughly 25 percent over the past 30 days, trading at €18.72, though the precise figure depends on the day's close. Both the 14-day and 30-day relative strength indicators — at 72.5 and 71.6 respectively — flag the shares as technically overbought, with the price now sitting about 25 percent above its 50-day moving average of €14.97.
Yet the rally only partially repairs earlier damage. The shares remain nearly half below their 52-week high of €36.05, reached in January, underscoring how much ground the recovery still has to cover. Market capitalisation stands at €17.72 billion.
The August Test
CSG's order book, last reported at roughly €17 billion, provides the fundamental case for the current valuation. But converting that backlog into revenue and profit is the challenge ahead. The half-year results due in August will be the first real test: the market will scrutinise whether the group can hold its targeted adjusted EBIT margin of 25 percent. Deliver on that, and the recent share-price momentum looks justified in hindsight. Miss it, and the overbought technical position could turn uncomfortable quickly.
For now, the financial terms of the North Vector Dynamics stake remain undisclosed, leaving investors to gauge its potential impact through the group's broader strategic narrative. The question is how quickly the Canadian partnership translates into concrete orders or technology transfers that strengthen CSG's own product range.
